Literature DB >> 9685458

The role of auxologic and growth factor measurements in the diagnosis of growth hormone deficiency.

R L Hintz1.   

Abstract

The use of auxologic measurements in the diagnosis of short stature in children has a long history in pediatric endocrinology, and they have even been used as the primary criteria in selecting children for growth hormone (GH) therapy. Certainly, an abnormality in the control of growth is more likely in short children than in children of normal stature. However, most studies have shown little or no value of auxologic criteria in differentiating short children who have classic growth hormone deficiency (GHD) from short children who do not. In National Cooperative Growth Study Substudy VI, in more than 6000 children being assessed for short stature, the overall mean height SD score was -2.5 +/- 1.1 and the body mass index standard deviation score was -0.5 +/- 1.4. However, there were no significant differences in these measures between the patients who were found subsequently to have GHD and those who were not. There also was no consistent difference in the growth rates between the patients with classic GHD and those short children without a diagnosis of GHD. This probably reflects the fact that we are dealing with a selected population of children who were referred for short stature and are further selecting those who are the shortest for additional investigation. Growth factor measurements have been somewhat more useful in selecting patients with GHD and have been proposed as primary diagnostic criteria. However, in National Cooperative Growth Study Substudy VI, only small differences in the levels of insulin-like growth factor I and insulin-like growth factor binding protein 3 were seen between the patients who were selected for GH treatment and those who were not. Many studies indicate that the primary value of growth factor measurements is to exclude patients who are unlikely to have GHD or to identify those patients in whom an expedited work-up should be performed. The diagnosis of GHD remains difficult and must be based on all of the data possible and the best judgment of an experienced clinician. Even under ideal circumstances, errors of both overdiagnosis and underdiagnosis of GHD still are likely.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9685458

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  4 in total

1.  Predicting the probability of abnormal stimulated growth hormone response in children after radiotherapy for brain tumors.

Authors:  Chiaho Hua; Shengjie Wu; Wassim Chemaitilly; Renin C Lukose; Thomas E Merchant
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-06       Impact factor: 7.038

2.  Selecting short-statured children needing growth hormone testing: derivation and validation of a clinical decision rule.

Authors:  Laëtitia Duché; Christine Trivin; Wassim Chemaitilly; Jean Claude Souberbielle; Gérard Bréart; Raja Brauner; Martin Chalumeau
Journal:  BMC Pediatr       Date:  2008-07-16       Impact factor: 2.125

3.  Development and Validation of a Prediction Rule for Growth Hormone Deficiency Without Need for Pharmacological Stimulation Tests in Children With Risk Factors.

Authors:  Florencia Clément; Romina P Grinspon; Daniel Yankelevich; Sabrina Martín Benítez; María Carolina De La Ossa Salgado; María Gabriela Ropelato; María Gabriela Ballerini; Ana C Keselman; Débora Braslavsky; Patricia Pennisi; Ignacio Bergadá; Gabriela P Finkielstain; Rodolfo A Rey
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-03       Impact factor: 5.555

4.  Discriminatory performance of insulin-like growth factor 1 and insulin-like growth factor binding protein-3 by correlating values to chronological age, bone age, and pubertal status for diagnosis of isolated growth hormone deficiency.

Authors:  Yu Jung Choi; Yoon Ji Lee; Na Yeong Lee; Seon-Hwa Lee; Seul-Ki Kim; Moon-Bae Ahn; Shin-Hee Kim; Won-Kyoung Cho; Kyoung-Soon Cho; Min Ho Jung; Byung-Kyu Suh
Journal:  Ann Pediatr Endocrinol Metab       Date:  2020-07-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.